{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:36:24Z","timestamp":1793144184858,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"S8","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00508-025-02590-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:59:29Z","timestamp":1759157969000},"page":"243-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Empfehlungen zur Diagnostik und Therapie der chronischen Nierenkrankheit (CKD) der \u00d6sterreichischen Gesellschaft f\u00fcr Nephrologie","Recommendations for the Diagnosis and Treatment of Chronic Kidney Disease (CKD) by the Austrian Society of Nephrology"],"prefix":"10.1007","volume":"137","author":[{"given":"Sara H.","family":"Ksiazek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schmaldienst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"10225","key":"2590_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","volume":"395","author":"P Cockwell","year":"2020","unstructured":"Cockwell\u00a0P, Fisher\u00a0LA. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662\u20134.","journal-title":"Lancet"},{"issue":"10225","key":"2590_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov\u00a0B, Purcell\u00a0CA, Levey\u00a0AS, Smith\u00a0M, Abdoli\u00a0A, Abebe\u00a0M, et\u00a0al. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a\u00a0systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"key":"2590_CR3","unstructured":"Franzen M, Wernly B, Salmhofer H, Iglseder B, Paulweber B, Trinka E, et\u00a0al. Paracelsus 10.000 \u2013 Pr\u00e4valenz der chronischen Niereninsuffizienz und geringe CKD-Awareness in \u00d6sterreich."},{"issue":"4","key":"2590_CR4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/ndt\/gfm790","volume":"23","author":"RP Obermayr","year":"2008","unstructured":"Obermayr\u00a0RP, Temml\u00a0C, Knechtelsdorfer\u00a0M, Gutjahr\u00a0G, Kletzmayr\u00a0J, Heiss\u00a0S, et\u00a0al. Predictors of new-onset decline in kidney function in a\u00a0general middle-european population. Nephrol Dial Transplant. 2008;23(4):1265\u201373.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2590_CR5","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens\u00a0PE, Ahmed\u00a0SB, Carrero\u00a0JJ, Foster\u00a0B, Francis\u00a0A, Hall\u00a0RK, et\u00a0al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):S117\u2013S314.","journal-title":"Kidney Int"},{"key":"2590_CR6","unstructured":"National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey, 2017-March 2020, Awareness of CKD by KDIGO Risk Categories."},{"issue":"5","key":"2590_CR7","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1016\/S2214-109X(16)00071-1","volume":"4","author":"B Ene-Iordache","year":"2016","unstructured":"Ene-Iordache\u00a0B, Perico\u00a0N, Bikbov\u00a0B, Carminati\u00a0S, Remuzzi\u00a0A, Perna\u00a0A, et\u00a0al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a\u00a0cross-sectional study. Lancet Glob Health. 2016;4(5):e307\u2013e19.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2590_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2011","unstructured":"Kovesdy\u00a0CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2011;12(1):7\u201311.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"2590_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.ackd.2017.09.003","volume":"25","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad\u00a0P, Karger\u00a0AB, Maahs\u00a0DM. Measured GFR in Routine Clinical Practice\u2014The Promise of Dried Blood Spots. Adv Chronic Kidney Dis. 2018;25(1):76\u201383.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"2590_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfac254","volume":"38","author":"RT Gansevoort","year":"2022","unstructured":"Gansevoort\u00a0RT, Anders\u00a0HJ, Cozzolino\u00a0M, Fliser\u00a0D, Fouque\u00a0D, Ortiz\u00a0A, et\u00a0al. What should European nephrology do with the new CKD-EPI equation? Nephrol Dial Transplant. 2022;38(1):1\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"2590_CR11","series-title":"5","first-page":"391","volume-title":"Ueber den Niederschlag, welchen Pikrins\u00e4ure in normalem Harn erzeugt und \u00fcber eine neue Reaction des Kreatinins","author":"M Jaffe","year":"1886","unstructured":"Jaffe\u00a0M. Ueber den Niederschlag, welchen Pikrins\u00e4ure in normalem Harn erzeugt und \u00fcber eine neue Reaction des Kreatinins. 5, Bd. 10. 1886. S.\u00a0391\u2013400."},{"issue":"11","key":"2590_CR12","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/ckj\/sfad178","volume":"16","author":"K Boss","year":"2023","unstructured":"Boss\u00a0K, Stolpe\u00a0S, M\u00fcller\u00a0A, Wagner\u00a0B, Wichert\u00a0M, Assert\u00a0R, et\u00a0al. Effect of serum creatinine difference between the Jaffe and the enzymatic method on kidney disease detection and staging. Clin Kidney\u00a0J. 2023;16(11):2147\u201355.","journal-title":"Clin Kidney J"},{"issue":"2","key":"2590_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1161\/CIRCHEARTFAILURE.109.856393","volume":"2","author":"MD McMurray","year":"2009","unstructured":"McMurray\u00a0MD, Trivax\u00a0JE, McCullough\u00a0PA. Serum Cystatin\u00a0C, Renal Filtration Function, and Left Ventricular Remodeling. Circ Heart Fail. 2009;2(2):86\u20139.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"2590_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1214234","volume":"369","author":"MG Shlipak","year":"2013","unstructured":"Shlipak\u00a0MG, Matsushita\u00a0K, \u00c4rnl\u00f6v\u00a0J, Inker\u00a0LA, Katz\u00a0R, Polkinghorne\u00a0KR, et\u00a0al. Cystatin\u00a0C versus creatinine in determining risk based on kidney function. N\u00a0Engl J Med. 2013;369(10):932\u201343.","journal-title":"N Engl J Med"},{"issue":"3","key":"2590_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7326\/M23-1138","volume":"177","author":"EL Fu","year":"2024","unstructured":"Fu\u00a0EL, Carrero\u00a0JJ, Sang\u00a0Y, Evans\u00a0M, Ishigami\u00a0J, Inker\u00a0LA, et\u00a0al. Association of Low Glomerular Filtration Rate With Adverse Outcomes at Older Age in a\u00a0Large Population With Routinely Measured Cystatin\u00a0C. Ann Intern Med. 2024;177(3):269\u201379.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2590_CR16","doi-asserted-by":"publisher","first-page":"17517","DOI":"10.1038\/s41598-022-22433-4","volume":"12","author":"E Herou","year":"2022","unstructured":"Herou\u00a0E, Grubb\u00a0A, Dardashti\u00a0A, Nozohoor\u00a0S, Zindovic\u00a0I, Ederoth\u00a0P, et\u00a0al. Reduced renal elimination of larger molecules is a\u00a0strong predictor for mortality. Sci Rep. 2022;12(1):17517.","journal-title":"Sci Rep"},{"issue":"10","key":"2590_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","volume":"151","author":"SE Claudel","year":"2025","unstructured":"Claudel\u00a0SE, Verma\u00a0A. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A\u00a0State-of-the-Art Review. Circulation. 2025;151(10):716\u201332.","journal-title":"Circulation"},{"issue":"1","key":"2590_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ajkd.2023.12.018","volume":"84","author":"N Rasaratnam","year":"2024","unstructured":"Rasaratnam\u00a0N, Salim\u00a0A, Blackberry\u00a0I, Cooper\u00a0ME, Magliano\u00a0DJ, van Wijngaarden\u00a0P, et\u00a0al. Urine Albumin-Creatinine Ratio Variability in People With Type\u00a02 Diabetes: Clinical and Research Implications. Am J Kidney Dis. 2024;84(1):8\u201317.e1.","journal-title":"Am J Kidney Dis"},{"key":"2590_CR19","unstructured":"World Health Organization, Regional Office for Europe, Policies EO HS, Sagan A, Sagan A, McDaid D, Rajan S, Farrington J, et\u00a0al. Screening: when is it appropriate and how can we get it right? (Internet). World Health Organization. Regional Office for Europe. 2020. https:\/\/apps.who.int\/iris\/handle\/10665\/330810. Zugegriffen: 3. Apr. 2023."},{"issue":"6","key":"2590_CR20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.7326\/M22-3228","volume":"176","author":"MM Cusick","year":"2023","unstructured":"Cusick\u00a0MM, Tisdale\u00a0RL, Chertow\u00a0GM, Owens\u00a0DK, Goldhaber-Fiebert\u00a0JD. Population-Wide Screening for Chronic Kidney Disease : A\u00a0Cost-Effectiveness Analysis. Ann Intern Med. 2023;176(6):788\u201397.","journal-title":"Ann Intern Med"},{"key":"2590_CR21","unstructured":"Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin e.\u202fV. (DEGAM), Deutsche Gesellschaft f\u00fcr Nephrologie e.\u202fV. (DGfN), Deutsche Gesellschaft f\u00fcr Innere Medizin e.\u202fV. (DGIM). S3-Leitlinie Versorgung von Patienten mit chronischer nicht-dialysepflichtiger Nierenerkrankung in der Hausarztpraxis https:\/\/register.awmf.org\/de\/leitlinien\/detail\/053-048. Zugegriffen: 14. Jan. 2025."},{"key":"2590_CR22","unstructured":"Recommendations | Chronic kidney disease: assessment and management | Guidance | NICE (Internet). NICE. 2021. https:\/\/www.nice.org.uk\/guidance\/ng203\/chapter\/Recommendations#risk-assessment-referral-criteria-and-shared-care. Zugegriffen: 3. Apr. 2023."},{"issue":"5","key":"2590_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3349\/ymj.2023.0306","volume":"65","author":"ES Koh","year":"2024","unstructured":"Koh\u00a0ES, Chung\u00a0S. Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease Transition. Yonsei Med\u00a0J. 2024;65(5):247\u201356.","journal-title":"Yonsei Med J"},{"issue":"12","key":"2590_CR24","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer\u00a0IH, Khunti\u00a0K, Sadusky\u00a0T, Tuttle\u00a0KR, Neumiller\u00a0JJ, Rhee\u00a0CM, et\u00a0al. Diabetes Management in Chronic Kidney Disease: A\u00a0Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"12","key":"2590_CR25","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia\u00a0G, Kreutz\u00a0R, Brunstr\u00f6m\u00a0M, Burnier\u00a0M, Grassi\u00a0G, Januszewicz\u00a0A, et\u00a0al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J\u00a0Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"key":"2590_CR26","unstructured":"Sammaritano LR, Askanase A, Bermas BL, Dall\u2019Era M, Duarte-Garc\u00eda A, Hiraki LT, et\u00a0al. American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol. 2024;2025."},{"issue":"2","key":"2590_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2015.18202","volume":"315","author":"N Tangri","year":"2016","unstructured":"Tangri\u00a0N, Grams\u00a0ME, Levey\u00a0AS, Coresh\u00a0J, Appel\u00a0LJ, Astor\u00a0BC, et\u00a0al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A\u00a0Meta-analysis. JAMA. 2016;315(2):164\u201374.","journal-title":"JAMA"},{"issue":"385","key":"2590_CR28","doi-asserted-by":"publisher","first-page":"e078063","DOI":"10.1136\/bmj-2023-078063","volume":"15","author":"P Liu","year":"2024","unstructured":"Liu\u00a0P, Sawhney\u00a0S, Heide-J\u00f8rgensen\u00a0U, Quinn\u00a0RR, Jensen\u00a0SK, Mclean\u00a0A, et\u00a0al. Predicting the risks of kidney failure and death in adults with moderate to severe chronic kidney disease: multinational, longitudinal, population based, cohort study. BMJ. 2024;15(385):e78063.","journal-title":"BMJ"},{"issue":"6","key":"2590_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.kint.2018.01.009","volume":"93","author":"ME Grams","year":"2018","unstructured":"Grams\u00a0ME, Sang\u00a0Y, Ballew\u00a0SH, Carrero\u00a0JJ, Djurdjev\u00a0O, Heerspink\u00a0HJL, et\u00a0al. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93(6):1442\u201351.","journal-title":"Kidney Int"},{"key":"2590_CR30","unstructured":"Chronic Kidney Disease (CKD). Early Identification and Intervention in Primary Care https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/PCP_1Page_English_1Side.pdf. Zugegriffen: 21. Mai 2024."},{"key":"2590_CR31","doi-asserted-by":"crossref","unstructured":"Rashid AM, Khan MS, Cherney DZI, Mehta A, Rangaswami J, Shafi T, et\u00a0al. Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type\u00a02 Diabetes. J\u00a0Am Soc Nephrol. 2025;.","DOI":"10.1681\/ASN.0000000752"},{"issue":"10","key":"2590_CR32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink\u00a0HJL, Perkins\u00a0BA, Fitchett\u00a0DH, Husain\u00a0M, Cherney\u00a0DZI. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"2","key":"2590_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington\u00a0WG, Staplin\u00a0N, Wanner\u00a0C, Green\u00a0JB, Hauske\u00a0SJ, et\u00a0al. Empagliflozin in Patients with Chronic Kidney Disease. N\u00a0Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"7","key":"2590_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney\u00a0DZI, Dekkers\u00a0CCJ, Barbour\u00a0SJ, Cattran\u00a0D, Gafor\u00a0AAH, Greasley\u00a0PJ, et\u00a0al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a\u00a0randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"2590_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"JL Heerspink Hiddo","year":"2020","unstructured":"Heerspink Hiddo\u00a0JL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0F\u2011F, et\u00a0al. Dapagliflozin in Patients with Chronic Kidney Disease. N\u00a0Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"11","key":"2590_CR36","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink\u00a0HJL, Jongs\u00a0N, Chertow\u00a0GM, Langkilde\u00a0AM, McMurray\u00a0JJV, Correa-Rotter\u00a0R, et\u00a0al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type\u00a02 diabetes: a\u00a0prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"2590_CR37","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD, Pitt\u00a0B, Ruilope\u00a0LM, Rossing\u00a0P, et\u00a0al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type\u00a02 Diabetes. N\u00a0Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"2590_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal\u00a0R, Kolkhof\u00a0P, Bakris\u00a0G, Bauersachs\u00a0J, Haller\u00a0H, Wada\u00a0T, et\u00a0al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart\u00a0J. 2021;42(2):152\u201361.","journal-title":"Eur Heart J"},{"key":"2590_CR39","doi-asserted-by":"crossref","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et\u00a0al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type\u00a02 Diabetes. N\u00a0Engl J Med. 2025;.","DOI":"10.1056\/NEJMoa2410659"},{"issue":"5","key":"2590_CR40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing\u00a0P, Caramori\u00a0ML, Chan\u00a0JCN, Heerspink\u00a0HJL, Hurst\u00a0C, Khunti\u00a0K, et\u00a0al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5):S1\u2013S127.","journal-title":"Kidney Int"},{"key":"2590_CR41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","author":"V Perkovic","year":"2024","unstructured":"Perkovic\u00a0V, Tuttle\u00a0KR, Rossing\u00a0P, Mahaffey\u00a0KW, Mann\u00a0JFE, Bakris\u00a0G, et\u00a0al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type\u00a02 Diabetes. N\u00a0Engl J Med. 2024; https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"11","key":"2590_CR42","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink\u00a0HJL, Sattar\u00a0N, Pavo\u00a0I, Haupt\u00a0A, Duffin\u00a0KL, Yang\u00a0Z, et\u00a0al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type\u00a02 diabetes in the SURPASS-4\u00a0trial: post-hoc analysis of an open-label, randomised, phase\u00a03\u00a0trial. Lancet Diabetes Endocrinol. 2022;10(11):774\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2590_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00508-023-02194-4","volume":"135","author":"M Resl","year":"2023","unstructured":"Resl\u00a0M. Leitlinien \u00d6sterreichische Diabetesgesellschaft. Wien Klin Wochenschr. 2023;135(1):1\u20136.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"2590_CR44","doi-asserted-by":"publisher","first-page":"ii36","DOI":"10.1093\/ckj\/sfae278","volume":"17","author":"M Theodorakopoulou","year":"2024","unstructured":"Theodorakopoulou\u00a0M, Ortiz\u00a0A, Fernandez-Fernandez\u00a0B, Kanbay\u00a0M, Minutolo\u00a0R, Sarafidis\u00a0PA. Guidelines for the management of hypertension in CKD patients: where do we stand in 2024? Clin Kidney\u00a0J. 2024;17(2):ii36\u2013ii50.","journal-title":"Clin Kidney J"},{"issue":"10302","key":"2590_CR45","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh\u00a0K, Jafar\u00a0TH, Nitsch\u00a0D, Neuen\u00a0BL, Perkovic\u00a0V. Chronic kidney disease. Lancet. 2021;398(10302):786\u2013802.","journal-title":"Lancet"},{"issue":"11","key":"2590_CR46","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali\u00a0C, Mallamaci\u00a0F, Adamczak\u00a0M, de Oliveira\u00a0RB, Massy\u00a0ZA, Sarafidis\u00a0P, et\u00a0al. Cardiovascular complications in chronic kidney disease: a\u00a0review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119(11):2017\u201332.","journal-title":"Cardiovasc Res"},{"key":"2590_CR47","doi-asserted-by":"crossref","unstructured":"Colombijn JMT, Idema DL, van Beem S, Blokland AM, van der Braak K, Handoko ML, et\u00a0al. Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease Medications: A\u00a0Systematic Review. JAMA Network Open. 2024;7(3).","DOI":"10.1001\/jamanetworkopen.2024.0427"},{"issue":"6","key":"2590_CR48","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner\u00a0C, Tonelli\u00a0M, et\u00a0al. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303\u20139.","journal-title":"Kidney Int"},{"issue":"25","key":"2590_CR49","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","unstructured":"SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart\u00a0J. 2021;42(25):2439\u201354.","journal-title":"Eur Heart J"},{"key":"2590_CR50","unstructured":"Anemia in CKD \u2013 KDIGO https:\/\/kdigo.org\/guidelines\/anemia-in-ckd\/. Zugegriffen: 21. Mai 2024."},{"key":"2590_CR51","unstructured":"DFP-Supplementum. Eisenmangel bei nicht-dialysepflichtiger chronischer Nierenerkrankung | \u00d6sterreichische \u00c4rztezeitung \u2013 \u00d6\u00c4Z https:\/\/aerztezeitung.at\/2023\/dfp\/2023\/dfp-supplementum-eisenmangel-bei-nicht-dialysepflichtiger-chronischer-nierenerkrankung\/. Zugegriffen: 19. Jan. 2025."},{"issue":"1","key":"2590_CR52","first-page":"1","volume":"7","author":"KDIGO","year":"2011","unstructured":"KDIGO. 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2014Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2011;7(1):1\u201359.","journal-title":"Kidney Int Suppl"},{"issue":"25","key":"2590_CR53","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","volume":"123","author":"A Alonso","year":"2011","unstructured":"Alonso\u00a0A, Lopez\u00a0FL, Matsushita\u00a0K, Loehr\u00a0LR, Agarwal\u00a0SK, Chen\u00a0LY, et\u00a0al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946\u201353.","journal-title":"Circulation"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02590-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02590-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02590-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T03:51:15Z","timestamp":1759204275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02590-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":53,"journal-issue":{"issue":"S8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2590"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02590-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"23 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.H.\u00a0Ksiazek gibt Sprecherhonorare von AstraZeneca und Boehringer Ingelheim an; M.\u00a0Windpessl: Sprecherhonorare von AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor; E.\u00a0Zitt: Beratungs- und Sprecherhonorare von: CSL Vifor, Boehringer Ingelheim, AstraZeneca, GSK, Novartis, Vantive; K.\u00a0Eller: Sprecherhonorar und Advisory Board Honorare von AstraZeneca und Boehringer Ingelheim; M.\u00a0Antlanger: Beratungs- und Sprecherhonorare von CSL Vifor, AstraZeneca, Boehringer Ingelheim, Bayer AG; D.\u00a0Cejka: Sprecherhonorare f\u00fcr AstraZeneca, Boehringer Ingelheim, Bayer; R.\u00a0Oberbauer: Sprecherhonorar von CSL Vifor, Advisory Board Honorare von Argenx, Neovii, Sanofi und Meeting Support von Neovii; M.D.\u00a0S\u00e4emann: Beratungs- und Sprecherhonorare von: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Eli Lilly, GSK, Novartis, Novo Nordisk, Otsuka. M.\u00a0Rudnicki, C.\u00a0Schwarz, S.\u00a0Schmaldienst und A.R.\u00a0Rosenkranz geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}